165659-77-8
Chemical Structure
Deacetoxyvinzolidine
Synonym(s): KAR-2
- CAS No.: 165659-77-8
- Formula:C46H56ClN5O7
- Molecular Weight:826.42
IUPAC Name: methyl (3R,5S,7R,9S)-9-((3aR,3a1S,5R,5aR,10bR)-3'-(2-chloroethyl)-3a-ethyl-8-methoxy-6-methyl-2',4'-dioxo-3a,3a1,5a,6,11,12-hexahydro-1H,4H-spiro[indolizino[8,1-cd]carbazole-5,5'-oxazolidin]-9-yl)-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indole-9-carboxylate
InChIKey: NUXKIZBEPYVRKP-RWBWKAGLSA-N
SMILES: CN1[C@]2([H])[C@]3(C4=CC([C@@]5(C6=C(CC[N@@]7C[C@](C[C@](O)(C7)CC)([H])C5)C8=CC=CC=C8N6)C(OC)=O)=C(OC)C=C41)[C@]9([H])[C@](C[C@]2%10C(N(C(O%10)=O)CCCl)=O)(C=CCN9CC3)CC
Biological Activity: Deacetoxyvinzolidine (KAR-2) is a bis-indol derivative with high anti-microtubular and anti-tumour activities. Deacetoxyvinzolidine exhibits high affinity for bovine purified brain tubulin (Kd of 3 μM) and inhibits microtubule assembly at a concentration of 10 nM. Deacetoxyvinzolidine does not possess anti-calmodulin activity. Deacetoxyvinzolidine can be used for the study of leukaemia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Deacetoxyvinzolidine | Deacetoxyvinzolidine (KAR-2) is a bis-indol derivative with high anti-microtubular and anti-tumour activities. Deacetoxyvinzolidine exhibits high affinity for bovine purified brain tubulin (Kd of 3 μM) and inhibits microtubule assembly at a concentration of 10 nM. Deacetoxyvinzolidine does not possess anti-calmodulin activity. Deacetoxyvinzolidine can be used for the study of leukaemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Orosz F, et al. The interaction of a new anti-tumour drug, KAR-2 with calmodulin. Br J Pharmacol. 1997 Jul;121(5):955-62. [Content Brief]
- [2]. Orosz F, et al. Interaction of a new bis-indol derivative, KAR-2 with tubulin and its antimitotic activity. Br J Pharmacol. 1997 Jul;121(5):947-54. [Content Brief]
